Adaptive Biotechnologies Corp Stock Alpha and Beta Analysis
| ADPT Stock | USD 16.17 0.26 1.63% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Adaptive Biotechnologies Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Adaptive Biotechnologies over a specified time horizon. Remember, high Adaptive Biotechnologies' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Adaptive Biotechnologies' market risk premium analysis include:
Beta 0.22 | Alpha 0.24 | Risk 4.8 | Sharpe Ratio 0.0348 | Expected Return 0.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Adaptive Biotechnologies Backtesting, Adaptive Biotechnologies Valuation, Adaptive Biotechnologies Correlation, Adaptive Biotechnologies Hype Analysis, Adaptive Biotechnologies Volatility, Adaptive Biotechnologies History and analyze Adaptive Biotechnologies Performance. Adaptive Biotechnologies Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Adaptive Biotechnologies market risk premium is the additional return an investor will receive from holding Adaptive Biotechnologies long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Adaptive Biotechnologies. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Adaptive Biotechnologies' performance over market.| α | 0.24 | β | 0.22 |
Adaptive Biotechnologies expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Adaptive Biotechnologies' Buy-and-hold return. Our buy-and-hold chart shows how Adaptive Biotechnologies performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Adaptive Biotechnologies Market Price Analysis
Market price analysis indicators help investors to evaluate how Adaptive Biotechnologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Adaptive Biotechnologies shares will generate the highest return on investment. By understating and applying Adaptive Biotechnologies stock market price indicators, traders can identify Adaptive Biotechnologies position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Stalled Pattern | ||
| Separating Lines |
Adaptive Biotechnologies Return and Market Media
The median price of Adaptive Biotechnologies for the period between Thu, Oct 9, 2025 and Wed, Jan 7, 2026 is 16.32 with a coefficient of variation of 9.53. The daily time series for the period is distributed with a sample standard deviation of 1.55, arithmetic mean of 16.31, and mean deviation of 1.22. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Pellini Michael J of 48044 shares of Adaptive Biotechnologies at 3.99 subject to Rule 16b-3 | 10/10/2025 |
2 | Adaptive Biotechnologies Corporations 31 percent Jump Shows Its Popularity With Investors | 10/16/2025 |
3 | Adaptive Biotechnologies Reports Q3 Earnings What Key Metrics Have to Say | 11/06/2025 |
4 | Disposition of 133032 shares by Sharon Benzeno of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 11/20/2025 |
5 | Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 18.94 subject to Rule 16b-3 | 12/01/2025 |
6 | Insider Selling Adaptive Biotechnologies CFO Sells 3,174,990.00 in Stock | 12/03/2025 |
7 | Adaptive Biotechnologies Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat | 12/08/2025 |
8 | Adaptive Biotechnologies Shares Up 6 percent Whats Next | 12/10/2025 |
9 | Disposition of 19423 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 12/15/2025 |
10 | How Adaptive Biotechnologies Corporation stock responds to policy changes - Market Activity Recap Fast Moving Stock Trade Plans - ulpravda.ru | 12/19/2025 |
11 | Disposition of 2194 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 12/22/2025 |
12 | Adaptive Biotechnologies Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals | 12/23/2025 |
13 | Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference | 12/30/2025 |
About Adaptive Biotechnologies Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Adaptive or other stocks. Alpha measures the amount that position in Adaptive Biotechnologies has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 9.79 | 9.92 | 8.93 | 7.27 | Days Of Inventory On Hand | 69.8 | 42.74 | 49.15 | 46.69 |
Adaptive Biotechnologies Upcoming Company Events
As portrayed in its financial statements, the presentation of Adaptive Biotechnologies' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptive Biotechnologies' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Adaptive Biotechnologies' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Adaptive Biotechnologies. Please utilize our Beneish M Score to check the likelihood of Adaptive Biotechnologies' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Adaptive Biotechnologies
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.